Dr. Li is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2 Wisconsin Cir
Suite 250
Chevy Chase, MD 20815Phone+1 301-986-9262Fax+1 301-907-7910
Education & Training
- Johns Hopkins UniversityFellowship, Allergy and Immunology, 2001
- Rutgers Health/Cooperman Barnabas Medical CenterResidency, Internal Medicine, 1999
- Rutgers Health/Cooperman Barnabas Medical CenterInternship, Internal Medicine, 1996 - 1997
- University of Texas Medical BranchPhD, 1992 - 1996
- University of Texas Medical BranchPhD, 1992 - 1996
- Tianjin Medical UniversityClass of 1988
Certifications & Licensure
- NJ State Medical License Current
- FL State Medical License 2024 - 2026
- MD State Medical License 1999 - 2026
- NY State Medical License 2023 - 2025
- DC State Medical License 2002 - 2024
- VA State Medical License 2023 - 2024
- American Board of Allergy and Immunology Allergy & Immunology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
Clinical Trials
- A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants Start of enrollment: 2014 May 14
- A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor Start of enrollment: 2021 Feb 05
Roles: Principal Investigator
Publications & Presentations
PubMed
- 11 citationsSubcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized studyH. Henry Li, Bruce L. Zuraw, Hilary Longhurst, Marco Cicardi, Konrad Bork
Allergy, Asthma, and Clinical Immunology. 2019-08-28 - 49 citationsPhase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrateBruce L. Zuraw, Marco Cicardi, Hilary Longhurst, Jonathan A. Bernstein, Huamin Henry Li
Allergy. 2015-10-01 - 23 citationsLanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.Marc A. Riedl, Marcus Maurer, Jonathan A. Bernstein, Aleena Banerji, Hilary Longhurst
Allergy. 2020-11-01
Journal Articles
- Effect of Lanadelumab Compared with Placebo on Prevention of Hereditary Angioedema AttacksJonathan A Bernstein, Lawrence B Schwartz, Andrew M Smith, H James Wedner, Daniel Soteres, Timothy Craig, Douglas T Johnston, Aleena Banerji, Paula J Busse, William R ..., JAMA
- Population Pharmacokinetics of Subcutaneous C1‐Inhibitor for Prevention of Attacks in Patients with Hereditary AngioedemaJonathan A Bernstein, Marc A Riedl, Bruce Zuraw, H Henry Li, Timothy Craig, William R Lumry, Clinical and experimental allergy
Professional Memberships
- Fellow
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: